Estimated read time: 2-3 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
BETHLEHEM, Pa.--(BUSINESS WIRE)--Mar 10, 2014--St. Luke’s University Health Network is one of three sites nationwide chosen to enroll patients in a new study using the therapeutic agent PV-10 for late-stage liver cancer. Sanjiv Agarwala, MD of St. Luke’s Cancer Center, internationally recognized melanoma investigator and Chief of Medical Oncology and Hematology for St. Luke’s University Health Network, serves as the principal investigator of this Phase I clinical trial.
Sanjiv Agarwala, MD of St. Luke's Cancer Center. (Photo: Business Wire)
PV-10 is a 10 percent solution of Rose Bengal, designed to selectively target and destroy cancer cells without harming surrounding healthy tissue. The drug, designed by Provectus Biopharmaceuticals, Inc., a development-stage biopharmaceutical company, has demonstrated positive results in clinical studies for melanoma, helping to prolong the lives of people with advanced disease. When injected into a lesion, PV-10 helps to control disease progression and inhibit growth. It also has been shown to elicit a positive bystander effect on nearby lesions that have not been injected.
“Since PV-10 has cleared Phase II testing for melanoma due to its proven effectiveness, it was time to evaluate the drug to see if it could benefit patients with other types of cancer who have exhausted standard treatment options,” says Dr. Agarwala.
According to Dr. Agarwala, the new PV-10 liver trial is open to adult patients with metastatic disease who have at least one liver lesion that has either originated in or spread to the liver and who have failed standard therapies. All patients enrolled in this open-label study receive the same treatment; a liver tumor is injected with the PV-10 solution. The procedure is performed by St. Luke’s interventional radiologist Ellen Redstone, MD.
St. Luke’s is also one of three sites nationwide to participate in the Compassionate Use study for PV-10 for people with late-stage cutaneous or subcutaneous cancers who have run out of treatment options. Compassionate use programs provide access to experimental therapeutic agents to patients before the investigational drugs receive final FDA approval. For more information, call St. Luke’s Network Clinical Trials office at 484-503-4151.
Photos/Multimedia Gallery Available:http://www.businesswire.com/multimedia/home/20140310006084/en/
CONTACT: St. Luke’s University Health Network
Sue Ross, 484-526-4122
Director, Marketing & Public Relations
susan.ross@sluhn.org
or
Denise Rader, 484-526-4104
Director, Network Media Relations
denise.rader@sluhn.org
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS HOSPITALS ONCOLOGY PHARMACEUTICAL FDA
SOURCE: St. Luke’s University Health Network
Copyright Business Wire 2014
PUB: 03/10/2014 01:00 PM/DISC: 03/10/2014 01:00 PM
http://www.businesswire.com/news/home/20140310006084/en
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
